Do analysts recommend PHIO or APLM?

Phio Pharmaceuticals presently has a consensus price target of $14.00, suggesting a potential upside of 1,161.26%. Given Phio Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Phio Pharmaceuticals is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phio Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, PHIO or APLM?

Phio Pharmaceuticals has higher earnings, but lower revenue than Apollomics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Phio Pharmaceuticals N/A N/A -$8.70M -$1.29 N/A Apollomics $8.50M 7.25 -$10.94M N/A N/A

Is PHIO or APLM more profitable?

Apollomics' return on equity of 0.00% beat Phio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Phio Pharmaceuticals N/A -87.41% -79.76% Apollomics N/A N/A N/A

Do analysts prefer ATYR or PHIO?

Phio Pharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 1,161.26%. Given Phio Pharmaceuticals' higher probable upside, analysts plainly believe Phio Pharmaceuticals is more favorable than aTyr Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score aTyr Pharma 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.25 Phio Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ATYR or PHIO more profitable?

Phio Pharmaceuticals' return on equity of -87.41% beat aTyr Pharma's return on equity. Company Net Margins Return on Equity Return on Assets aTyr Pharma N/A -95.89% -69.67% Phio Pharmaceuticals N/A -87.41% -79.76%

Does the media favor ATYR or PHIO?

In the previous week, Phio Pharmaceuticals had 1 more articles in the media than aTyr Pharma. MarketBeat recorded 5 mentions for Phio Pharmaceuticals and 4 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 0.50 beat Phio Pharmaceuticals' score of -0.80 indicating that aTyr Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment aTyr Pharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Phio Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Do analysts recommend ALPS or PHIO?

Phio Pharmaceuticals has a consensus price target of $14.00, indicating a potential upside of 1,161.26%. Given Phio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Phio Pharmaceuticals is more favorable than ALPS Group Inc Ordinary Share. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALPS Group Inc Ordinary Share 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Phio Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ALPS or PHIO more profitable?

ALPS Group Inc Ordinary Share's return on equity of 0.00% beat Phio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets ALPS Group Inc Ordinary Share N/A N/A N/A Phio Pharmaceuticals N/A -87.41% -79.76%

Which has higher earnings & valuation, TIL or PHIO?

Instil Bio is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Instil Bio N/A N/A -$71.37M -$4.47 N/A Phio Pharmaceuticals N/A N/A -$8.70M -$1.29 N/A

Is TIL or PHIO more profitable?

Instil Bio's return on equity of -26.78% beat Phio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Instil Bio N/A -26.78% -14.89% Phio Pharmaceuticals N/A -87.41% -79.76%

Does the media prefer PHIO or TCRX?

In the previous week, Phio Pharmaceuticals and Phio Pharmaceuticals both had 5 articles in the media. TScan Therapeutics' average media sentiment score of -0.61 beat Phio Pharmaceuticals' score of -0.80 indicating that TScan Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phio Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative TScan Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Negative

Phio Pharmaceuticals (PHIO) Competitors

$1.11 -0.02 (-1.77%)

As of 09/3/2026 04:00 PM Eastern

Compare

PHIO vs. APLM, ATYR, ALPS, TIL, and TCRX

Should you buy Phio Pharmaceuticals stock or one of its competitors? Phio Pharmaceuticals's main competitors and comparable companies include Apollomics (APLM), aTyr Pharma (ATYR), ALPS Group Inc Ordinary Share (ALPS), Instil Bio (TIL), and TScan Therapeutics (TCRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Phio Pharmaceuticals compare to Apollomics?

Phio Pharmaceuticals (NASDAQ:PHIO) and Apollomics (NASDAQ:APLM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

Phio Pharmaceuticals has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market. Comparatively, Apollomics has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market.

57.3% of Phio Pharmaceuticals shares are held by institutional investors. Comparatively, 19.1% of Apollomics shares are held by institutional investors. 3.5% of Phio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Apollomics' return on equity of 0.00% beat Phio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-87.41%	-79.76%
Apollomics	N/A	N/A	N/A

Phio Pharmaceuticals has higher earnings, but lower revenue than Apollomics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.29	N/A
Apollomics	$8.50M	7.25	-$10.94M	N/A	N/A

In the previous week, Phio Pharmaceuticals had 5 more articles in the media than Apollomics. MarketBeat recorded 5 mentions for Phio Pharmaceuticals and 0 mentions for Apollomics. Apollomics' average media sentiment score of 0.00 beat Phio Pharmaceuticals' score of -0.80 indicating that Apollomics is being referred to more favorably in the news media.

Company	Overall Sentiment
Phio Pharmaceuticals	Negative
Apollomics	Neutral

Phio Pharmaceuticals presently has a consensus price target of $14.00, suggesting a potential upside of 1,161.26%. Given Phio Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Phio Pharmaceuticals is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Phio Pharmaceuticals beats Apollomics on 7 of the 12 factors compared between the two stocks.

How does Phio Pharmaceuticals compare to aTyr Pharma?

aTyr Pharma (NASDAQ:ATYR) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

Phio Pharmaceuticals has lower revenue, but higher earnings than aTyr Pharma. Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	259.94	-$74.12M	-$0.62	N/A
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.29	N/A

aTyr Pharma has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market. Comparatively, Phio Pharmaceuticals has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market.

Phio Pharmaceuticals' return on equity of -87.41% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-95.89%	-69.67%
Phio Pharmaceuticals	N/A	-87.41%	-79.76%

Phio Pharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 1,161.26%. Given Phio Pharmaceuticals' higher probable upside, analysts plainly believe Phio Pharmaceuticals is more favorable than aTyr Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Phio Pharmaceuticals had 1 more articles in the media than aTyr Pharma. MarketBeat recorded 5 mentions for Phio Pharmaceuticals and 4 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 0.50 beat Phio Pharmaceuticals' score of -0.80 indicating that aTyr Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
aTyr Pharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Phio Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

61.7% of aTyr Pharma shares are held by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are held by institutional investors. 5.8% of aTyr Pharma shares are held by insiders. Comparatively, 3.5% of Phio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

aTyr Pharma beats Phio Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Phio Pharmaceuticals compare to ALPS Group Inc Ordinary Share?

ALPS Group Inc Ordinary Share (NASDAQ:ALPS) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

27.9% of ALPS Group Inc Ordinary Share shares are owned by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are owned by institutional investors. 25.5% of ALPS Group Inc Ordinary Share shares are owned by company insiders. Comparatively, 3.5% of Phio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Phio Pharmaceuticals has a consensus price target of $14.00, indicating a potential upside of 1,161.26%. Given Phio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Phio Pharmaceuticals is more favorable than ALPS Group Inc Ordinary Share.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALPS Group Inc Ordinary Share	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

ALPS Group Inc Ordinary Share has a beta of -0.1, indicating that its stock price is 110% less volatile than the broader market. Comparatively, Phio Pharmaceuticals has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market.

ALPS Group Inc Ordinary Share's return on equity of 0.00% beat Phio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALPS Group Inc Ordinary Share	N/A	N/A	N/A
Phio Pharmaceuticals	N/A	-87.41%	-79.76%

In the previous week, Phio Pharmaceuticals had 5 more articles in the media than ALPS Group Inc Ordinary Share. MarketBeat recorded 5 mentions for Phio Pharmaceuticals and 0 mentions for ALPS Group Inc Ordinary Share. ALPS Group Inc Ordinary Share's average media sentiment score of 0.00 beat Phio Pharmaceuticals' score of -0.80 indicating that ALPS Group Inc Ordinary Share is being referred to more favorably in the media.

Company	Overall Sentiment
ALPS Group Inc Ordinary Share	Neutral
Phio Pharmaceuticals	Negative

ALPS Group Inc Ordinary Share has higher revenue and earnings than Phio Pharmaceuticals. Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than ALPS Group Inc Ordinary Share, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALPS Group Inc Ordinary Share	$4.86M	13.01	-$2.01M	$0.33	1.15
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.29	N/A

Summary

ALPS Group Inc Ordinary Share beats Phio Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Phio Pharmaceuticals compare to Instil Bio?

Instil Bio (NASDAQ:TIL) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Instil Bio's return on equity of -26.78% beat Phio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-26.78%	-14.89%
Phio Pharmaceuticals	N/A	-87.41%	-79.76%

60.6% of Instil Bio shares are held by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are held by institutional investors. 47.0% of Instil Bio shares are held by insiders. Comparatively, 3.5% of Phio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Instil Bio has a beta of 1.91, meaning that its stock price is 91% more volatile than the broader market. Comparatively, Phio Pharmaceuticals has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market.

Instil Bio is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$4.47	N/A
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.29	N/A

In the previous week, Phio Pharmaceuticals had 5 more articles in the media than Instil Bio. MarketBeat recorded 5 mentions for Phio Pharmaceuticals and 0 mentions for Instil Bio. Instil Bio's average media sentiment score of 0.00 beat Phio Pharmaceuticals' score of -0.80 indicating that Instil Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Instil Bio	Neutral
Phio Pharmaceuticals	Negative

Instil Bio presently has a consensus target price of $66.00, suggesting a potential upside of 761.62%. Phio Pharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 1,161.26%. Given Phio Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Phio Pharmaceuticals is more favorable than Instil Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Phio Pharmaceuticals beats Instil Bio on 7 of the 13 factors compared between the two stocks.

How does Phio Pharmaceuticals compare to TScan Therapeutics?

Phio Pharmaceuticals (NASDAQ:PHIO) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

57.3% of Phio Pharmaceuticals shares are owned by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are owned by institutional investors. 3.5% of Phio Pharmaceuticals shares are owned by company insiders. Comparatively, 6.3% of TScan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Phio Pharmaceuticals and Phio Pharmaceuticals both had 5 articles in the media. TScan Therapeutics' average media sentiment score of -0.61 beat Phio Pharmaceuticals' score of -0.80 indicating that TScan Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phio Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
TScan Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Negative

Phio Pharmaceuticals has higher earnings, but lower revenue than TScan Therapeutics. Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.29	N/A
TScan Therapeutics	$10.32M	2.44	-$129.77M	-$0.91	N/A

Phio Pharmaceuticals currently has a consensus target price of $14.00, suggesting a potential upside of 1,161.26%. TScan Therapeutics has a consensus target price of $4.67, suggesting a potential upside of 1,158.20%. Given Phio Pharmaceuticals' higher probable upside, research analysts plainly believe Phio Pharmaceuticals is more favorable than TScan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
TScan Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Phio Pharmaceuticals has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market.

Phio Pharmaceuticals has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,655.35%. Phio Pharmaceuticals' return on equity of -87.41% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-87.41%	-79.76%
TScan Therapeutics	-1,655.35%	-108.72%	-54.47%

Summary

TScan Therapeutics beats Phio Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Get Phio Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHIO vs. The Competition

Export

Metric	Phio Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$13.13M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-0.86	12.66	273.29	25.38
Price / Sales	N/A	1,309.08	613.45	97.56
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	1.03	16.29	12.89	6.14
Net Income	-$8.70M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-1.77%	0.34%	0.60%	-0.27%
1 Month Performance	4.72%	8.52%	5.73%	0.68%
1 Year Performance	-46.12%	52.66%	25.35%	14.84%

Phio Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHIO Phio Pharmaceuticals	3.2983 of 5 stars	$1.11 -1.8%	$14.00 +1,161.3%	-46.6%	$13.13M	N/A	N/A	10
APLM Apollomics	1.5906 of 5 stars	$24.92 +7.8%	N/A	+569.3%	$55.18M	$8.50M	N/A	45	Analyst Downgrade
ATYR aTyr Pharma	0.3469 of 5 stars	$0.56 +4.7%	N/A	-91.2%	$54.44M	$190K	N/A	53	Gap Up
ALPS ALPS Group Inc Ordinary Share	0.5647 of 5 stars	$0.32 +1.6%	N/A	N/A	$53.25M	$4.86M	0.97	N/A	Gap Up
TIL Instil Bio	1.7925 of 5 stars	$7.70 -1.4%	$66.00 +757.1%	-73.6%	$52.21M	N/A	N/A	410

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHIO) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Phio Pharmaceuticals (PHIO) Competitors

PHIO vs. APLM, ATYR, ALPS, TIL, and TCRX

How does Phio Pharmaceuticals compare to Apollomics?

Summary

How does Phio Pharmaceuticals compare to aTyr Pharma?

Summary

How does Phio Pharmaceuticals compare to ALPS Group Inc Ordinary Share?

Summary

How does Phio Pharmaceuticals compare to Instil Bio?

Summary

How does Phio Pharmaceuticals compare to TScan Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHIO vs. The Competition

Phio Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Phio Pharmaceuticals (PHIO) Competitors

PHIO vs. APLM, ATYR, ALPS, TIL, and TCRX

How does Phio Pharmaceuticals compare to Apollomics?

Which has more risk and volatility, PHIO or APLM?

Do insiders & institutionals believe in PHIO or APLM?

Is PHIO or APLM more profitable?

Which has higher earnings & valuation, PHIO or APLM?

Does the media prefer PHIO or APLM?

Do analysts recommend PHIO or APLM?

Summary

How does Phio Pharmaceuticals compare to aTyr Pharma?

Which has stronger earnings and valuation, ATYR or PHIO?

Which has more risk and volatility, ATYR or PHIO?

Is ATYR or PHIO more profitable?

Do analysts prefer ATYR or PHIO?

Does the media favor ATYR or PHIO?

Do insiders and institutionals hold more shares of ATYR or PHIO?

Summary

How does Phio Pharmaceuticals compare to ALPS Group Inc Ordinary Share?

Do insiders & institutionals have more ownership in ALPS or PHIO?

Do analysts recommend ALPS or PHIO?

Which has more risk and volatility, ALPS or PHIO?

Is ALPS or PHIO more profitable?

Does the media prefer ALPS or PHIO?

Which has stronger valuation & earnings, ALPS or PHIO?

Summary

How does Phio Pharmaceuticals compare to Instil Bio?

Is TIL or PHIO more profitable?

Do insiders and institutionals hold more shares of TIL or PHIO?

Which has more volatility & risk, TIL or PHIO?

Which has higher earnings & valuation, TIL or PHIO?

Does the media favor TIL or PHIO?

Do analysts rate TIL or PHIO?

Summary

How does Phio Pharmaceuticals compare to TScan Therapeutics?

Do insiders & institutionals hold more shares of PHIO or TCRX?

Does the media prefer PHIO or TCRX?

Which has better valuation & earnings, PHIO or TCRX?

Do analysts recommend PHIO or TCRX?

Which has more volatility & risk, PHIO or TCRX?

Is PHIO or TCRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHIO vs. The Competition

Phio Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools